bivv020
mAbexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04269551)
Timeline
Indications
Mechanism of action
- Complement C1sINHIBITOR
C1S inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315038 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06859099 | Phase 3 | Apr 1, 2025 | Sanofi |
| NCT06290141 | Phase 3 | Aug 21, 2024 | Sanofi |
| NCT06290128 | Phase 3 | Jul 12, 2024 | Sanofi |
| NCT05156710 | Phase 2 | Jan 14, 2022 | Sanofi |
| NCT04802057 | Phase 1 | Mar 22, 2021 | Sanofi, Sanofi-Aventis |
| NCT04669600 | Phase 2 | Jan 31, 2021 | Sanofi, Sanofi-Aventis |
| NCT04658472 | Phase 2 | Jan 21, 2021 | Sanofi |
| NCT04269551 | Phase 1 | Feb 29, 2020 | Sanofi |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 8 | 6 | 3 | 2020 |
| Sanofi-Aventis | For profit | 2 | 2 | 2 | 2021 |
2 organizations
Page 1 / 1